Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection-Reference-Cited by-同舟云学术

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

Published:2019-08-23 Issue:6 Volume:106 Page:1319-1327
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Mohamed Mohamed‐Eslam F.¹,Klünder Ben²,Camp Heidi S.³,Othman Ahmed A.¹^ORCID

Affiliation:

1. Clinical Pharmacology and Pharmacometrics AbbVie North Chicago Illinois USA

2. Clinical Pharmacology and Pharmacometrics AbbVie Deutschland GmbH & Co. KG Ludwigshafen am Rhein Germany

3. Immunology Clinical Development AbbVie North Chicago Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1543

Reference28 articles.

1. Janus kinase inhibitors in autoimmune diseases

2. Janus kinases in immune cell signaling

3. Selective JAK inhibitors in development for rheumatoid arthritis

4. Novel therapies for immune‐mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?;Baker K.F.;Ann. Rheum. Dis.,2017

5. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review;Journal of Clinical Medicine;2023-02-21

2. Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review;Annals of Pharmacotherapy;2022-08-02

3. Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials;Clinical and Translational Science;2021-10-27

4. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects;Clinical Pharmacology in Drug Development;2021-06-09

5. Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses;The Journal of Clinical Pharmacology;2020-12-05